Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities

Vista sencilla de ítem
dc.creatorWang, James Jiqi
dc.creatorEdin, Matthew L.
dc.creatorZeldin, Darryl C.
dc.creatorLi, Chenze
dc.creatorWang, Dao Wen
dc.creatorChen, Chen
dc.date.accessioned2020-09-11T15:19:29Z
dc.date.available2020-09-11T15:19:29Z
dc.date.created2020-05-09
dc.description.abstractenglishThe coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin–angiotensin–aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful.spa
dc.format.extent9 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.pharmthera.2020.107628spa
dc.identifier.issn0163-7258spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/13162
dc.language.isoengspa
dc.publisherPharmacology & Therapeuticsspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectRAAS inhibitorsspa
dc.subjectHypertensionspa
dc.subjectBradykininspa
dc.subjectInflammationspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleGood or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbiditiesspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Good or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdf
Tamaño:
1023.25 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS